M 201-A - Aetas Pharma

Drug Profile

M 201-A - Aetas Pharma

Latest Information Update: 27 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aetas Pharma
  • Developer Aetas Pharma; Kitasato University
  • Class Antiarrhythmics
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atrial fibrillation

Most Recent Events

  • 19 Feb 2017 Phase-I clinical trials in Atrial fibrillation (In volunteers) in Japan (IV) (NCT03055403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top